

Taxol (Paclitaxel): A Promising Alkaloid for Cancer Treatment

Anna Maria Barbuti¹, Zhe-Sheng Chen^{1*}

¹Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY 11439, USA.

*E-mail ✉ chenz@stjohns.edu

Received: 24 November 2022; Revised: 20 January 2023; Accepted: 24 January 2023

ABSTRACT

Taxol, derived from the plant alkaloid paclitaxel, is a prominent anticancer agent. It acts by inhibiting microtubule formation and preventing cancer cell division. The intravenous administration of Taxol has been well established, particularly in the treatment of solid tumors. However, prolonged use of the drug often leads to reduced efficacy due to the emergence of resistance in cancer cells. Furthermore, the side effects of Taxol can vary depending on individual factors such as age, genetics, and general health. To overcome these challenges, researchers have investigated various formulations, including nanocomplexes, to address drug resistance and minimize adverse effects. These developments have shown promise in improving Taxol's therapeutic effectiveness. In addition to its primary use in oncology, Taxol has also been investigated for its potential in other medical fields, expanding its clinical applications. This editorial highlights the importance of Taxol in cancer treatment and emphasizes the need for ongoing research to combat resistance and expand its use in contemporary medicine.

Keywords: Taxol, Paclitaxel, Microtubule disruption, Mitotic inhibitor, Cancer

How to Cite This Article: Barbuti AM, Chen ZS. Taxol (Paclitaxel): A Promising Alkaloid for Cancer Treatment. Pharm Sci Drug Des. 2023;3:1-2. <https://doi.org/10.51847/aD0CrEg6Fo>

Paclitaxel (C₄₇H₅₁NO₁₄) is an anti-cancer agent from the taxane family, originally derived from the Pacific yew tree (*Taxus brevifolia*), which belongs to the Taxaceae family. Approved by the FDA in 1993, it has been included in the World Health Organization's list of essential medicines. Marketed as Taxol, paclitaxel has shown effectiveness against a variety of cancers, including lung, breast, ovarian, bladder, prostate, melanoma, cervical, esophageal, pancreatic, colorectal cancers, and Kaposi sarcoma [1, 2].

As a taxane, paclitaxel disrupts microtubule functions—key structures responsible for various essential cellular functions like division, movement, and structural integrity. By stabilizing tubulin bound to GDP, it prevents the disassembly of microtubules, blocking mitotic spindle formation and halting cell division. Like other anticancer agents such as vincristine, vinblastine, and colchicine, paclitaxel functions as a mitotic inhibitor, though it acts differently on microtubule dynamics. Additionally, paclitaxel triggers apoptosis by inhibiting the Bcl-2 protein, which regulates cell survival [3, 4].

Typically administered intravenously, paclitaxel can be formulated with albumin, alcohol, or emulsifiers to improve solubility. Its cytotoxic effect is dependent on both the concentration and exposure time. Studies have shown that ascorbic acid enhances paclitaxel's anticancer potential in human breast cancer cells. Caffeic acid phenethyl ester (CAPE), known for its selective estrogen receptor modulator activity, increases paclitaxel's ability to induce apoptosis in prostate cancer cells (PC-3, DU-145, and LNCaP) [5]. A conjugate of paclitaxel with a cell-penetrating peptide (Taxol-CPP) has been developed into nanospheres, demonstrating cytotoxicity against HepG2 cancer cells. A nanoparticle formulation of paclitaxel, named Nanoxel, has also been approved in India [4]. Furthermore, in animal studies involving non-small cell lung cancer (NSCLC), paclitaxel and cisplatin-loaded nanoparticles have shown improved control over tumor progression [6].

The prolonged use of Taxol is often limited by the development of drug resistance. In colorectal cancer cells, an elevated expression of TXNDC17 has been linked to resistance. Taxol treatment induces an increase in phospho-STAT3 and TXNDC17 levels [6]. Studies have shown that Taxol-resistant cells exhibit higher levels of TAK1 (transforming growth factor- β -activated kinase 1). Interestingly, Taxol-oligoarginine conjugates are more

effective against Taxol-resistant human ovarian cancer specimens [6]. In addition to resistance, Taxol can cause a variety of adverse effects, which can impact patient adherence to treatment. These include skin reactions like hives, respiratory issues such as wheezing, hair problems (e.g., alopecia), muscle and joint pain, tingling, dizziness, peripheral neuropathy, diarrhea, infertility in females, and bone marrow suppression. Vascular complications can also occur, and the drug may pose risks to fetal development when used during pregnancy. Due to its limited solubility in water, Taxol is frequently combined with Cremophor as a formulation vehicle, but this combination can cause further unwanted side effects. Therefore, continuous pharmacovigilance is crucial to monitor potential interactions with other medications and herbs [6].

In addition to being derived from the *Taxus* plant, Taxol has also been identified in several fungi, including the endophytic species *Paraconiothyrium variable* and *Epicoccum nigrum*. Other fungi, such as *Metarhizium anisopliae*, *Pestalotiopsis microspora* NK17, and *Cladosporium* species, have been shown to produce Taxol when cultured. *Cladosporium cladosporioides* MD2 can generate up to 800 µg/L of Taxol, and *Aspergillus aculeatinus* Tax-6 has also been found to produce the compound in controlled environments. The biosynthetic genes for Taxol have been identified, including *dbat* and *pga1*. Beyond the *Taxus* species, paclitaxel has been detected in hazel plants from the Betulaceae family. In plants, paclitaxel is produced via the terpenoid pathway. Semisynthetic Taxol is produced using baccatin III, a plant metabolite, as well as through plant cell culture techniques and bacterial metabolic engineering. Aside from its primary use in cancer treatment, Taxol is also used for therapeutic purposes such as in Taxol-eluting stents for treating vascular diseases [6]. Therefore, further research into alternative applications and methods to reduce its side effects is necessary. **Figure 1** provides a detailed illustration of Taxol's biological mechanism.




Figure 1. General mechanism of taxol anticancer mechanism

Acknowledgments: None

Conflict of Interest: None

Financial Support: None

Ethics Statement: None

References

1. Ahmed Khalil A, Rauf A, Alhumaydhi FA, Aljohani AS, Javed MS, Khan MA, et al. Recent developments and anticancer therapeutics of paclitaxel: an update. *Curr Pharm Des.* 2022;28(41):3363-73.
2. Weaver BA. How Taxol/paclitaxel kills cancer cells. *Mol Biol Cell.* 2014;25(18):2677-81.
3. Stanton RA, Gernert KM, Nettles JH, Aneja R. Drugs that target dynamic microtubules: a new molecular perspective. *Med Res Rev.* 2011;31(3):443-81.
4. Kasai S, Sasaki T, Watanabe A, Nishiya M, Yasuhira S, Shibazaki M, et al. Bcl-2/Bcl-xL inhibitor ABT-737 sensitizes pancreatic ductal adenocarcinoma to paclitaxel-induced cell death. *Oncol Lett.* 2017;14(1):903-8.
5. Kurbacher CM, Wagner U, Kolster B, Andreotti PE, Krebs D, Bruckner HW. Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro. *Cancer Lett.* 1996;103(2):183-9.
6. Tolba MF, Esmat A, Al-Abd AM, Azab SS, Khalifa AE, Mosli HA, et al. Caffeic acid phenethyl ester synergistically enhances docetaxel and paclitaxel cytotoxicity in prostate cancer cells. *IUBMB Life.* 2013;65(8):716-29.